Horizon Discovery, Otsuka Pharmaceutical deal

Horizon said its CombinatoRx division received a contract from Otsuka to perform in vitro cell line screening of undisclosed development candidates. Horizon said it will be paid $835,000 for work to be “substantially completed” this year. The company declined to comment on specific research plans, but said the CombinatoRx platform is frequently used to screen development candidates in combination with other agents to “identify patterns of synergy that may help to guide development efforts.” Otsuka declined to comment on the deal. ...